European equities traded in the US as American depositary receipts were lower late Friday morning, declining 0.22% to 1,373.53 on the S&P Europe Select ADR Index. From continental Europe, the gainers ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nurix Therapeutics (NRIX – Research Report), ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

In a report released today, Arthur He CFA from H.C. Wainwright maintained a Buy rating on Adaptimmune Therapeutics (ADAP – Research Report), ...

Adaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 86% if they invested five years ago ...

Adaptimmune, the T-cell therapy specialist ... as fludarabine had been linked with patient deaths in a trial of Juno Therapeutics’ T-cell treatment, JCAR015, in a leukaemia trial.

This transaction was part of a "Sell to Cover" exercise, automatically implemented to satisfy tax withholding obligations and associated costs. Following this transaction, Mr. Lunger retains ownership ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

1 Day ADAP -1.71% DJIA 0.78% Russell 2K 0.40% Health Care/Life Sciences 66.70% ...